Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEXT-Bone substudy of adjuvant endocrine therapy effects on bone mineral density
ACTRN12609000532202Phase 3Terminated
- Sponsor
- Breast Cancer Trials
- Start
- Nov 2009
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, exemestane and triptorelin in breast cancer (2 arms), sponsored by Breast Cancer Trials. Primary endpoint: Change in bone mineral density. Started Nov 2009; status: terminated.
02
Drugs
tamoxifenexemestanetriptorelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12609000532202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000532202.